Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer
Citing Guo, Zenan Fan, Cuiyan Guo, Yaning Yang, Helei Hou, Dantong Sun · 2026
Read Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer by Citing Guo, Zenan Fan, Cuiyan Guo, Yaning Yang, Helei Hou, Dantong Sun (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13277278.txt.
Description
Citing Guo leads a 2026 review of a cancer protein called PD-L1 when it appears inside the cell nucleus. PD-L1 is best known on the cell surface, where it helps tumors hide from the immune system. Inside the nucleus, it seems to act on the cancer cell itself, without that immune route.
Nuclear PD-L1 has been linked to aggressive disease, resistance to treatment, and poor outcomes in several cancers. It may aid DNA repair, shift cell fuel use, and reshape nearby tissue. Measuring it well is still hard, and firm proof in patients is limited. The authors outline drugs that could block its move into the nucleus or its actions there, as a future treatment path.
Catalog record
| CREATOR | Citing Guo, Zenan Fan, Cuiyan Guo, Yaning Yang, Helei Hou, Dantong Sun |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85459 |
| LICENSE | https://creativecommons.org/publicdomain/zero/1.0 |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |